Advertisement
U.S. markets closed
  • S&P Futures

    5,208.00
    -6.75 (-0.13%)
     
  • Dow Futures

    39,202.00
    -21.00 (-0.05%)
     
  • Nasdaq Futures

    18,184.50
    -47.00 (-0.26%)
     
  • Russell 2000 Futures

    2,047.40
    -2.40 (-0.12%)
     
  • Crude Oil

    82.69
    -0.03 (-0.04%)
     
  • Gold

    2,165.30
    +1.00 (+0.05%)
     
  • Silver

    25.34
    +0.08 (+0.30%)
     
  • EUR/USD

    1.0877
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    4.3400
    +0.0360 (+0.84%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2724
    -0.0005 (-0.04%)
     
  • USD/JPY

    149.2350
    +0.1370 (+0.09%)
     
  • Bitcoin USD

    66,089.39
    -1,477.66 (-2.19%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    39,556.37
    -184.07 (-0.46%)
     

Sunesis Pharmaceuticals Q4 Earnings Preview

On Thursday, Sunesis Pharmaceuticals (NASDAQ: SNSS) will report its last quarter's earnings. Here is Benzinga's take on the company's release.

Earnings and Revenue

Sunesis Pharmaceuticals EPS loss will likely be near 29 cents while revenue will be around $150,000, according to analysts.

Sunesis Pharmaceuticals' loss in the same period a year ago was 44 cents. Quarterly sales came in at $676,000. Revenue would be down 77.81 percent on a year-over-year basis.

View more earnings on SNSS

Here's how the Sunesis Pharmaceuticals's reported EPS has stacked up against analyst estimates in the past:

Quarter

Q3 2017

Q2 2017

Q1 2017

Q4 2016

EPS Estimate

-0.37

-0.59

-0.69

-0.43

EPS Actual

-0.43

-0.41

-0.47

-0.44

Stock Performance

Over the last 52-week period, shares are up 68.15 percent. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.

Analyst estimates have adjusted higher for EPS and revenues over the past 90 days. The most common rating by analysts on Sunesis Pharmaceuticals stock is a Neutral. The strength of this rating has maintained conviction over the past three months.

Conference Call

Sunesis Pharmaceuticals' Q4 conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here.

See more from Benzinga

© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement